The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927)
Open accessAbstract
Purpose To compare 2 stereotactic body radiotherapy (SBRT) schedules for medically inoperable early-stage lung cancer to determine which produces the lowest rate of grade ≥ 3 protocol-specified adverse events (psAEs) at 1 year. Methods Patients with biopsy-proven peripheral (greater than 2 cm from the central bronchial tree) T1/T2, N0 (clinically node negative by positron emission tomography), M0 tumors were eligible. Patients were randomized to receive either 34 Gy in one fraction (Arm 1) or 48 Gy in 4 consecutive daily fractions (Arm 2). Rigorous central accreditation and quality assurance confirmed treatment per protocol guidelines. This study was designed to detect a psAEs rate > 17% at a 10% significance level (1-sided) and 90% power. Secondary endpoints included rates of primary tumor control (PC), overall survival (OS) and disease-free survival (DFS) at 1 year. Designating the better of the two regimens was based on pre-specified rules of psAEs and PC for each Arm. Results Ninety four patients were accrued between September 2009 and March 2011. Median follow up time was 30.2 months. Of 84 analyzable patients, 39 were in Arm 1 and 45 in Arm 2. Patient and tumor characteristics were balanced between Arms. Four (10.3%) patients on Arm 1 (95% confidence interval (CI): 2.9%-24.2%) and six (13.3%) patients on Arm 2 (95% CI: 5.1%-26.8%) experienced psAEs. The 2-year OS rate was 61.3% (95% CI: 44.2%-74.6%) for Arm 1 patients and 77.7% (95% CI: 62.5%-87.3%) for Arm 2. The 2-year DFS was 56.4% (95% 39.6%-70.2%) for Arm 1 and 71.1% (95% CI: 55.5%-82.1%) for Arm 2. The 1-year PC rate was 97.0% (95% CI: 84.2%-99.9%) for Arm 1 and 92.7% (80.1%-98.5%) for Arm 2. Conclusions 34 Gy in 1 fraction met pre-specified criteria and of the two schedules, warrants further clinical research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
CLOPPER, C. J., & PEARSON, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,003
Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer
Timmerman, R. (2010) · JAMA · doi:10.1001/jama.2010.261 · Cited by 2,532
Timmerman, R., McGarry, R., Yiannoutsos, C., Papiez, L., Tudor, K., DeLuca, J., Ewing, M., Abdulrahman, R., DesRosiers, C., Williams, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.5937 · Cited by 1,556
American Joint Committee On Cancer (2010) · Springer eBooks · doi:10.1007/978-0-387-88443-1 · Cited by 1,386
One-Sample Multiple Testing Procedure for Phase II Clinical Trials
Fleming, T. R. (1982) · Biometrics · doi:10.2307/2530297 · Cited by 1,003
Onishi, H., Shirato, H., Nagata, Y., Hiraoka, M., Fujino, M., 五味, 光., Niibe, Y., Karasawa, K., Hayakawa, K., Takai, Y., et al. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318074de34 · Cited by 989
Onishi, H., Araki, T., Shirato, H., Nagata, Y., Hiraoka, M., Gomi, K., Yamashita, T., Niibe, Y., Karasawa, K., Hayakawa, K., et al. (2004) · Cancer · doi:10.1002/cncr.20539 · Cited by 891
Nagata, Y., Takayama, K., Matsuo, Y., Norihisa, Y., Mizowaki, T., Sakamoto, T., Sakamoto, M., Mitsumori, M., Shibuya, K., Araki, N., et al. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.05.034 · Cited by 672
Extracranial Stereotactic Radioablation *
Timmerman, R., Papiez, L., McGarry, R., Likes, L., DesRosiers, C., Frost, S., & Williams, M. (2003) · Chest · doi:10.1378/chest.124.5.1946 · Cited by 671
Cited by
Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer
Chaft, J. E., Rimner, A., Weder, W., Azzoli, C. G., Kris, M. G., & Cascone, T. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00501-4 · Cited by 375
Videtic, G. M., Paulus, R., Singh, A. K., Chang, J. Y., Parker, W., Olivier, K. R., Timmerman, R. D., Komaki, R. R., Urbanic, J. J., Stephans, K. L., et al. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.11.051 · Cited by 294
Self-citationHigh Dose per Fraction, Hypofractionated Treatment Effects in the Clinic (HyTEC): an overview
Grimm, J., Marks, L. B., Jackson, A., Kavanagh, B. D., Xue, J., & Yorke, E. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.10.039 · Cited by 153
Metadata
- Authors
- Videtic, G. M. M., Hu, C., Singh, A. K., Chang, J. Y., Parker, W., Olivier, K. R., Schild, S. E., Komaki, R., Urbanic, J. J., & Choy, H.
- Venue
- International Journal of Radiation Oncology*Biology*Physics
- Publisher
- Elsevier BV
- Published
- 2015-11
- Volume
- 93
- Issue
- 4
- Pages
- 757-764
- ISSN
- 0360-3016 (ISSN-L)
- OpenAlex
- W2131441386
- Cited by
- 414
- References
- 18
- FWCI
- 26.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927). https://app.cochat.ai/papers/10.1016/j.ijrobp.2015.07.2260
- The paper
- Videtic, G. M. M., Hu, C., Singh, A. K., Chang, J. Y., Parker, W., Olivier, K. R., Schild, S. E., Komaki, R., Urbanic, J. J., & Choy, H. (2015). A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927). International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2015.07.2260
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.